ABSTRACT
Magnetostrictive Co77Fe23 films are fully suspended to produce free-standing, clamped-clamped, microbeam resonators. A negative or positive shift in the resonant frequency is observed for magnetic fields applied parallel or perpendicular to the length of the beam, respectively, confirming the magnetoelastic nature of the shift. Notably, the resonance shifts linearly with higher-bias fields oriented perpendicular to the beam's length. Domain imaging elucidates the distinction in the reversal processes along the easy and hard axes. Together, these results suggest that through modification of the magnetic anisotropy, the frequency shift and angular dependence can be tuned, producing highly magnetic-field-sensitive resonators.
ABSTRACT
Multifunctional materials composed of ultrathin magnetic films with perpendicular magnetic anisotropy combined with ferroelectric substrates represent a new approach toward low power, fast, high density spintronics. Here we demonstrate Co/Ni multilayered films with tunable saturation magnetization and perpendicular anisotropy grown directly on ferroelectric PZT [Pb(Zr0.52Ti0.48)O3] substrate plates. Electric fields up to ±2 MV/m expand the PZT by 0.1% and generate at least 0.02% in-plane compression in the Co/Ni multilayered film. Modifying the strain with a voltage can reduce the coercive field by over 30%. We also demonstrate that alternating in-plane tensile and compressive strains (less than 0.01%) can be used to propagate magnetic domain walls. This ability to manipulate high anisotropy magnetic thin films could prove useful for lowering the switching energy for magnetic elements in future voltage-controlled spintronic devices.
ABSTRACT
In ferroelectrics, manifestation of a strong electromechanical coupling is attributed to both engineered domain morphology and phase transformations. However, realization of large sustainable and reversible strains and polarization rotation has been limited by fatigue, nonlinearity and hysteresis losses. Here, we demonstrate that large strain and polarization rotation can be generated for over 40 × 10(6) cycles with little fatigue by realization of a reversible ferroelectric-ferroelectric phase transition in [011] cut Pb(In1/2Nb1/2)O3-Pb(Mg1/3Nb2/3)O3-PbTiO3 (PIN-PMN-PT) relaxor ferroelectric single crystal. Direct tuning of this effect through combination of stress and applied electric field, confirmed both macroscopically and microscopically with x-ray and Raman scattering, reveals the local symmetry while sweeping through the transition with a low applied electric field (<0.2 MV/m) under mechanical stress. The observed change in local symmetry as determined by x-ray scattering confirms a proposed polarization rotation mechanism corresponding to a transition between rhombohedral and orthorhombic phases. These results shed more light onto the nature of this reversible transformation between two ferroelectric phases and advance towards the development of a wide range of ferroic and multiferroic devices.
ABSTRACT
Powder samples of solid solution TbMn1-xCrxO3 (0 ≤ x ≤ 1) were synthesized via a facile solution route. The substitution of non-JahnTeller active Cr3+ for Mn3+ in TbMnO3 was found to decrease the unit cell volume and orthorhombic distortion. TbMn1-xCrxO3 with low Cr content (x ≤ 0.33) exhibited magnetic behavior similar to the pure TbMnO3 sample. However, ferromagnetic-like MnCr interactions were introduced in these samples and maximum magnetic field coercivity and remanence were found at x ~0.33. For x ≥ 0.5, signatures of a canted G-type antiferromagnetic ordering similar to pure TbCrO3 were observed. The Mn3+/Cr3+ spins rotate from parallel to the a-axis to parallel to the c-axis with increasing Cr content. Based on the magnetization results, a magnetic phase diagram for bulk solid solution TbMn1-xCrxO3 has been proposed for the first time.
ABSTRACT
Many magnetic materials lack intrinsic biocompatibility and require surface functionalization for in vivo applications. In this study, we fabricated an intrinsically biocompatible, biodegradable magnetic material through iron substitution into hydroxyapatite (FeHA) via ion-exchange. Controlling the oxidation state of iron in the ion exchange solution resulted in 'tunable' magnetic properties. Superparamagnetic behavior was observed in Fe2+HA and Fe2+3+HA and paramagnetism in Fe3+HA. FeHA powders were characterized using field emission scanning electron microscopy (FESEM), X-ray diffraction (XRD), Fourier transform infra-red (FTIR) and X-ray photoelectron spectroscopy (XPS) with no detection of iron oxide phases. The as-synthesized HA and Fe2+3+HA samples were characterized in vitro using MC3T3-E1 cells. Cellular proliferation of Fe2+3+HA was found comparable to HA, while our cytotoxicity results from a lactate dehydrogenase assay showed Fe2+3+HA to be less toxic than pure HA, a widely used implantable biomaterial. Thus, these results collectively suggest that we have fabricated a magnetic biomaterial with intrinsic biocompatibility.
ABSTRACT
Substitution of Ca(2+) and Sr(2+) at the A-site of multiferroic TbMnO3 bulk results in an increased average ionic radius and ionic-size mismatch, and was found to reduce the orthorhombic distortion. Signatures of long-range ferromagnetic-like ordering at 78 K in Tb0.67Ca0.33MnO3 and at 87 K in Tb0.67Sr0.33MnO3 samples are clearly observed in both the dc and ac susceptibility data. A compensation temperature is also observed in Tb0.67Ca0.33MnO3, indicating the antiparallel alignment of Tb(3+) moments to the Mn(3+)-Mn(4+) moments. The canted antiferromagnetic ordering coexists with antiferromagnetic clusters, resulting in spin-glass-like behavior at low temperatures. An increased average ionic radius and ionic-size mismatch at the A-site are determined to be critical factors in determining the magnetic properties of the hole-doped manganites.
Subject(s)
Calcium/chemistry , Glass/chemistry , Magnesium Oxide/chemistry , Magnetics , Magnets/chemistry , Strontium/chemistry , Terbium/chemistry , Antacids/chemistry , TemperatureABSTRACT
The chemokine receptors CCR5 and CXCR4 act synergistically with CD4 in an ordered multistep mechanism to allow the binding and entry of human immunodeficiency virus type 1 (HIV-1). The efficiency of such a coordinated mechanism depends on the spatial distribution of the participating molecules on the cell surface. Immunoelectron microscopy was performed to address the subcellular localization of the chemokine receptors and CD4 at high resolution. Cells were fixed, cryoprocessed, and frozen; 80-nm cryosections were double labeled with combinations of CCR5, CXCR4, and CD4 antibodies and then stained with immunogold. Surprisingly, CCR5, CXCR4, and CD4 were found predominantly on microvilli and appeared to form homogeneous microclusters in all cell types examined, including macrophages and T cells. Further, while mixed microclusters were not observed, homogeneous microclusters of CD4 and the chemokine receptors were frequently separated by distances less than the diameter of an HIV-1 virion. Such distributions are likely to facilitate cooperative interactions with HIV-1 during virus adsorption to and penetration of human leukocytes and have significant implications for development of therapeutically useful inhibitors of the entry process. Although the mechanism underlying clustering is not understood, clusters were observed in small trans-Golgi vesicles, implying that they were organized shortly after synthesis and well before insertion into the cellular membrane. Chemokine receptors normally act as sensors, detecting concentration gradients of their ligands and thus providing directional information for cellular migration during both normal homeostasis and inflammatory responses. Localization of these sensors on the microvilli should enable more precise monitoring of their environment, improving efficiency of the chemotactic process. Moreover, since selectins, some integrins, and actin are also located on or in the microvillus, this organelle has many of the major elements required for chemotaxis.
Subject(s)
CD4 Antigens/metabolism , HIV-1/metabolism , Macrophages/metabolism , Microvilli/metabolism , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , T-Lymphocytes/metabolism , Animals , CD4 Antigens/genetics , Cell Line , Cells, Cultured , Fluorescent Antibody Technique , Golgi Apparatus/metabolism , HIV Antibodies/immunology , HIV Envelope Protein gp120/metabolism , HIV-1/physiology , Humans , Macrophages/cytology , Macrophages/ultrastructure , Macrophages/virology , Membrane Microdomains/metabolism , Membrane Microdomains/ultrastructure , Microscopy, Electron, Scanning , Microscopy, Immunoelectron , Microvilli/ultrastructure , Rabbits , Receptors, CCR2 , Receptors, CCR5/genetics , Receptors, CXCR4/genetics , Receptors, Chemokine/metabolism , Secretory Vesicles/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/ultrastructure , T-Lymphocytes/virology , ThermodynamicsABSTRACT
The voltage-gated potassium channel, Kv1.3, is specifically expressed on human lymphocytes, where it controls membrane potential and calcium influx. Blockade of Kv1.3 channels by margatoxin was previously shown to prevent T cell activation and attenuate immune responses in vivo. In the present study, a triterpene natural product, correolide, was found to block Kv1.3 channels in human and miniswine T cells by electrophysiological characterization. T cell activation events, such as anti-CD3-induced calcium elevation, IL-2 production, and proliferation were inhibited by correolide in a dose-dependent manner. More potent analogs were evaluated for pharmacokinetic profiles and subsequently tested in a delayed-type hypersensitivity (DTH) response to tuberculin in the miniswine. Two compounds were dosed orally, iv, or im, and both compounds suppressed DTH responses, demonstrating that small molecule blockers of Kv1.3 channels can act as immunosuppressive agents in vivo. These studies establish correolide and its derivatives as novel immunosuppressants.
Subject(s)
Immunosuppressive Agents/pharmacology , Potassium Channel Blockers , Potassium Channels, Voltage-Gated , Potassium Channels , T-Lymphocytes/drug effects , Triterpenes/pharmacology , Animals , Humans , Immunosuppressive Agents/chemistry , Ion Channel Gating , Kv1.3 Potassium Channel , Molecular Structure , Swine , Swine, Miniature , T-Lymphocytes/immunology , Triterpenes/chemistryABSTRACT
Hypothemycin, a resorcylic acid lactone antibiotic, was identified as active in a screen for inhibitors of T cell activation. It was found to inhibit the proliferation of mouse and human T cells stimulated with anti-CD3 mAb + PMA and of human PBMC stimulated with anti-CD3 mAb alone. This inhibition was partially reversed by exogenous IL-2 indicating that it is not due to non-specific toxicity. Hypothemycin potently suppressed the production of IL-2 (IC50: 9 nM) but affected IL-2-induced proliferation to a lesser extent (IC50: 194 nM). Hypothemycin also inhibited IL-6, IL-10, IFN-gamma and TNF-alpha production. By contrast, it markedly enhanced the production of IL-4, IL-5 and IL-13. These effects were seen both at the mRNA and protein secretion levels. Analysis of the effect of hypothemycin on CD69 induction suggested that it disrupts calcineurin-independent rather than calcineurin-dependent signaling. Furthermore, hypothemycin was able to inhibit the phosphorylation of ERK1/2 induced by PMA treatment of T cells. Therefore, hypothemycin represents an inhibitor of T cell activation with a novel mode of action and unique modulatory activity on cytokine production.
Subject(s)
Antineoplastic Agents/pharmacology , Cytokines/drug effects , Immunosuppressive Agents/pharmacology , Lymphocyte Activation/drug effects , RNA, Messenger/drug effects , T-Lymphocytes/drug effects , Animals , Cytokines/metabolism , Estrogens, Non-Steroidal/pharmacology , Humans , Mice , RNA, Messenger/metabolism , T-Lymphocytes/metabolism , Tacrolimus/pharmacology , Zearalenone/pharmacologyABSTRACT
A tether length study of C32-O-phenalkyl ether derivatives of ascomycin was conducted wherein it was determined that a 2-carbon tether provides optimum in vitro immunosuppressive activity. Oxygen-bearing substituents along the 2-carbon tether can further increase the potency of this design.
Subject(s)
Immunosuppressive Agents/chemical synthesis , Immunosuppressive Agents/pharmacology , Macrolides/chemical synthesis , Macrolides/pharmacology , Tacrolimus/analogs & derivatives , Animals , Cell Division/drug effects , Drug Design , Drug Evaluation, Preclinical , Immunophilins/metabolism , Immunosuppressive Agents/metabolism , Inhibitory Concentration 50 , Structure-Activity Relationship , T-Lymphocytes/drug effects , Tacrolimus/chemistry , Tacrolimus/pharmacology , Tacrolimus Binding ProteinsABSTRACT
The synthesis of C32-O-arylethyl ether derivatives of ascomycin that possess equivalent immunosuppressant activity but reduced toxicity, compared to FK-506, is described.
Subject(s)
Immunosuppressive Agents/chemical synthesis , Immunosuppressive Agents/pharmacology , Macrolides/chemical synthesis , Macrolides/pharmacology , Tacrolimus/analogs & derivatives , Administration, Oral , Animals , Calcineurin Inhibitors , Drug Evaluation, Preclinical , Hypothermia/chemically induced , Immunophilins/metabolism , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/toxicity , Inhibitory Concentration 50 , Injections, Intravenous , Kidney Diseases/chemically induced , Male , Mice , Mice, Inbred BALB C , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , T-Lymphocytes/drug effects , Tacrolimus/chemistry , Tacrolimus/pharmacology , Tacrolimus/toxicity , Tacrolimus Binding Proteins , Toxicity TestsABSTRACT
Cytokine production upon T cell activation results from the integration of multiple signaling pathways from TCR/CD3 and from costimulatory molecules such as CD28. Among these pathways, the possible role of p38 mitogen activated protein kinase (MAPK) is the least understood. Here, we used a highly specific p38 MAPK inhibitor, the SB203580 compound, to examine the role of this enzyme in the induction of various cytokines in human T cells stimulated with anti-CD3 and anti-CD28 mAb together or in combination with PMA. Cytokine induction was monitored by ELISA and at the mRNA level. While SB203580 had little effect on IL-2 production and proliferation, it significantly reduced the production of several other cytokines. The secretion of IL-4, IL-5, IL-13, and TNF-alpha was inhibited by 20-50% with modes of T cell activation involving the CD28 pathway, whereas their mRNA expression was little affected. In contrast, IFN-gamma induction via CD28/PMA or CD3/CD28, but not CD3/PMA, was markedly diminished both at the protein and at the mRNA levels. Most interestingly, SB203580 also suppressed IL-10 secretion and mRNA induction via CD28-dependent activation by 75-85% (IC50 approximately 0.2 microM). Subset analysis suggested that this inhibition did not reflect a differential effect on T cell subsets. Therefore, p38 MAPK activity appears to contribute to cytokine production, mostly via CD28-dependent signaling. Moreover, IL-10 seems to rely more on this activity than other cytokines for its induction in T cells.
Subject(s)
CD28 Antigens/physiology , Calcium-Calmodulin-Dependent Protein Kinases/physiology , Cytokines/biosynthesis , Interleukin-10/biosynthesis , Mitogen-Activated Protein Kinases , T-Lymphocytes/metabolism , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Cells, Cultured , Cytokines/genetics , Dose-Response Relationship, Drug , Humans , Imidazoles/pharmacology , Interferon-gamma/biosynthesis , Interleukin-2/biosynthesis , Lymphocyte Activation/drug effects , Pyridines/pharmacology , RNA, Messenger/analysis , p38 Mitogen-Activated Protein KinasesABSTRACT
IP10 and MIG are two members of the CXC branch of the chemokine superfamily whose expression is dramatically up-regulated by interferon (IFN)-gamma. The proteins act largely on natural killer (NK)-cells and activated T-cells and have been implicated in mediating some of the effects of IFN-gamma and lipopolysaccharides (LPSs), as well as T-cell-dependent anti-tumor responses. Recently both chemokines have been shown to be functional agonists of the same G-protein-coupled receptor, CXCR3. We now report the pharmacological characterization of CXCR3 and find that, when heterologously expressed, CXCR3 binds IP10 and MIG with Ki values of 0.14 and 4.9 nM, respectively. The receptor has very modest affinity for SDF-1alpha and little or no affinity for other CXC-chemokines. The properties of the endogenous receptor expressed on activated T-cells are similar. Surprisingly, several CC-chemokines, particularly eotaxin and MCP-4, also compete with moderate affinity for the binding of IP10 to CXCR3. Eotaxin does not activate CXCR3 but, in CXCR3-transfected cells, can block IP10-mediated receptor activation. Eotaxin, therefore, may be a natural CXCR3 antagonist.
Subject(s)
Chemokines, CC , Intercellular Signaling Peptides and Proteins , Receptors, Chemokine/metabolism , T-Lymphocytes/metabolism , Animals , CHO Cells , Chemokine CCL11 , Chemokine CCL5/metabolism , Chemokine CCL7 , Chemokine CXCL10 , Chemokine CXCL9 , Chemokines, CXC/metabolism , Chemotactic Factors, Eosinophil/metabolism , Cloning, Molecular , Cricetinae , Cytokines/metabolism , Humans , Interferon-gamma/pharmacology , Lymphocyte Activation , Monocyte Chemoattractant Proteins/metabolism , Protein Binding , Receptors, CXCR3 , Receptors, Cytokine/metabolism , Recombinant Proteins/metabolism , Up-RegulationABSTRACT
Productive T cell activation leading to cytokine secretion requires the cooperation of multiple signaling pathways coupled to the TCR and to costimulatory molecules such as CD28. Here, we utilized two pharmacophores, PD98059 and FK506, that inhibit, respectively, mitogen-activated protein (MAP) kinase kinase 1 (MEK 1) and calcineurin, to determine the relative role of the signaling pathways controlled by these enzymes in T cell activation. Although the two compounds had distinctive effects on CD69 induction, they both suppressed T cell proliferation induced by anti-CD3 mAb, in a manner reversible by exogenous IL-2, suggesting that PD98059, like FK506, affects the production of, rather than the responsiveness to growth-promoting cytokines. Accordingly, IL-2 production by T cells stimulated with anti-CD3 mAb in conjunction with PMA or with anti-CD28 mAb was inhibited by both compounds. However, these compounds differentially affected the production of other cytokines, depending on the mode of activation. PD98059 inhibited TNF-alpha, IL-3, granulocyte-macrophage (GM)-CSF, IFN-gamma, and to a lesser extent IL-6 and IL-10 production but enhanced IL-4, IL-5, and IL-13 production induced by CD3/PMA or CD3/CD28. FK506 suppressed CD3/PMA-induced production of all cytokines examined here but to a lesser extent IL-13. FK506 also reduced CD3/CD28-induced production of IL-3, IL-4, IL-10, TNF-alpha, and IL-6 but augmented that of GM-CSF, IL-5, IFN-gamma, and IL-13. Therefore, the biochemical targets of PD98059 and FK506 contribute differently to the production of various cytokines by T cells, which may have implications for the therapeutic manipulation of this production.
Subject(s)
Calcineurin/physiology , Cytokines/biosynthesis , Lymphocyte Activation , Mitogen-Activated Protein Kinase Kinases , Protein Serine-Threonine Kinases/physiology , Protein-Tyrosine Kinases/physiology , T-Lymphocytes/immunology , CD28 Antigens/physiology , CD3 Complex/physiology , Cells, Cultured , Cytokines/genetics , Flavonoids/pharmacology , Humans , MAP Kinase Kinase 1 , Phosphorylation , RNA, Messenger/analysis , Tacrolimus/pharmacology , Tetradecanoylphorbol Acetate/pharmacologyABSTRACT
BACKGROUND: Tacrolimus (FK506) has potent immunosuppressive properties reflecting its ability to block the transcription of lymphokine genes in activated T cells through formation of a complex with FK506 binding protein-12, which inhibits the phosphatase activity of calcineurin. The clinical usefulness of tacrolimus is limited, however, by severe adverse effects, including neurotoxicity and nephrotoxicity. Although this toxicity, like immunosuppression, appears mechanistically related to the calcineurin inhibitory action of the drug, a large chemistry effort has been devoted to search for tacrolimus analogs with reduced toxicity but preserved immunosuppressive activity that might have enhanced therapeutic utility. METHODS: Here, we report on the identification of such an analog, which was synthetically derived from ascomycin (ASC), the C21 ethyl analog of tacrolimus, by introducing an indole group at the C32 position. The profile of biological activity of indolyl-ASC was characterized in rodent models of immunosuppression and toxicity. RESULTS: Indolyl-ASC was found to exhibit an immunosuppressive potency equivalent to that of tacrolimus in T-cell activation in vitro and in murine transplant models, even though indolyl-ASC bound about 10 times less to intracellular FK506 binding protein-12 than tacrolimus or ASC. Further evaluation of indolyl-ASC revealed that it is threefold less potent than tacrolimus in inducing hypothermia, a response that may reflect neurotoxicity, and in causing gastrointestinal transit alterations in mice. Moreover, indolyl-ASC was at least twofold less nephrotoxic than tacrolimus upon 3-week oral treatment in rats. CONCLUSIONS: Altogether, these data indicate a modest but definite improvement in the therapeutic index for indolyl-ASC compared with tacrolimus in rodent models.
Subject(s)
Immunosuppressive Agents/pharmacology , Tacrolimus/analogs & derivatives , Animals , Blood Urea Nitrogen , Body Temperature/drug effects , Cell Division/drug effects , Female , Immunosuppressive Agents/toxicity , Ionomycin/pharmacology , Kidney/drug effects , Kidney/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Tacrolimus/pharmacology , Tacrolimus/toxicity , Thyroid Gland/transplantationABSTRACT
Calcineurin (CaN) controls the production of multiple cytokines, including IL-2 and TNF-alpha, during T cell activation. However, its role in chemokine production is unclear. Here, we used the CaN inhibitor FK506 to probe for the contribution of CaN in MIP-1alpha, MIP-1beta, and RANTES production at the protein and mRNA levels in human T cells stimulated via CD3/PMA or CD3/CD28. With both modes of activation, FK506 inhibited RANTES production only partially and late during a 3-day culture, whereas it suppressed both MIP-1alpha and MIP-1beta production throughout the culture. However, FK506 inhibition was more pronounced on MIP-1beta than MIP-1alpha, especially in CD3/CD28-activated T cells. Surprisingly, FK506 also significantly reduced MIP-1beta induction by PMA alone. Furthermore, comparison with IL-2 and TNF-alpha revealed that both were more potently inhibited by the drug upon CD3/PMA or CD3/CD28 induction than either MIP-1alpha or MIP-1beta. These differences in FK506 sensitivity were also observed in CD4(+) and CD8(+) T cell subsets. Therefore, all three chemokines are affected by FK506 distinctly from one another and from IL-2 and TNF-alpha, suggesting that CaN participates to different extents in the induction of these cytokines during T cell activation. Further evidence that this induction relies on distinctive mechanisms, depending on the cytokine, came from analyses of the kinetics and cycloheximide sensitivity of cytokine mRNA expression.
Subject(s)
Calcineurin/physiology , Cytokines/biosynthesis , Lymphocyte Activation , T-Lymphocytes/immunology , CD28 Antigens/metabolism , CD3 Complex/metabolism , Calcineurin Inhibitors , Cells, Cultured , Chemokine CCL3 , Chemokine CCL4 , Chemokine CCL5/biosynthesis , Chemokine CCL5/genetics , Cycloheximide/pharmacology , Cytokines/genetics , Dose-Response Relationship, Drug , Gene Expression , Humans , Interferon-gamma/biosynthesis , Interleukin-2/biosynthesis , Macrophage Inflammatory Proteins/biosynthesis , Macrophage Inflammatory Proteins/genetics , Mitogens/metabolism , Mitogens/pharmacology , Protein Synthesis Inhibitors/pharmacology , RNA, Messenger , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Tacrolimus/pharmacology , Tetradecanoylphorbol Acetate/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
A series of C32-O-aralkyl ether derivatives of the FK-506 related macrolide ascomycin have been prepared based on an earlier reported C32-O-cinnamyl ether design. In the present study, the nature of the aryl tethering group was varied in an attempt to improve oral activity. An imidazol-2-yl-methyl tether was found to be superior among those investigated and has resulted in an ascomycin analog, L-733,725, with in vivo immunosuppressive activity comparable to FK-506 but with an improved therapeutic index.
Subject(s)
Imidazoles/chemical synthesis , Immunosuppressive Agents/chemical synthesis , Tacrolimus/analogs & derivatives , Tacrolimus/chemical synthesis , Animals , Biological Availability , Hypothermia/chemically induced , Imidazoles/pharmacology , Imidazoles/toxicity , Immunophilins/metabolism , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/toxicity , Indicators and Reagents , Kidney/drug effects , Kidney/pathology , Mice , Mice, Inbred BALB C , Molecular Conformation , Molecular Structure , Neurotoxins/toxicity , Rats , Structure-Activity Relationship , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Tacrolimus/pharmacology , Tacrolimus/therapeutic use , Tacrolimus/toxicity , Tacrolimus Binding ProteinsABSTRACT
FK-506 blocks T cell activation by preventing lymphokine gene transcription through formation of a complex with FKBP12 that inhibits calcineurin phosphatase activity. Immunosuppressive FK-506 analogs (agonists) have been generated whose potency correlates with calcineurin inhibition. Nonimmunosuppressive antagonist analogs have also been identified, including L-685,818, which binds to FKBP12 but does not inhibit calcineurin. We describe a novel property of FK-506 analog, characterized as a mixed agonist/antagonist immunosuppressive activity. It is displayed by L-688,617, the 32 O-methoxyethoxymethyl derivative of the agonist L-683,590 (C21-ethyl). Although it binds to FKBP12 similarly to L-683,590, L-688,617 incompletely suppressed T cell proliferation induced by optimal activation and enhanced that induced by supraoptimal activation. In the latter situation, L-688,617 suppressed IL-2 production only partially but blocked activation-driven cell death. Moreover, a 1000-fold molar excess of L-688,617 antagonized the immunosuppressive activity of L-683,590. L-688,617 inhibited calcineurin phosphatase activity in cells only partially. The unique agonist/antagonist activity of L-688,617 may therefore reflect its high affinity for FKBP12, combined with a reduced ability of the drug-FKBP12 complex to inhibit calcineurin function. However, in a cell-free system, L-688,617 completely blocked this function when a large excess of FKBP12 over calcineurin was present, suggesting that the intracellular concentration of FKBP12 may be a limiting factor that prevents full agonist activity of L-688,617 in cells.
Subject(s)
Immunosuppressive Agents/pharmacology , T-Lymphocytes/drug effects , Tacrolimus/analogs & derivatives , Tacrolimus/pharmacology , Animals , Binding, Competitive , Cells, Cultured/drug effects , Dose-Response Relationship, Drug , Female , Interleukin-2/metabolism , Mice , Mice, Inbred C57BL , Nigericin/analogs & derivatives , Nigericin/pharmacologyABSTRACT
Rapamycin (RAP) disrupts signaling events implicated in cytokine-dependent proliferation of lymphocytes and other cells. This action is known to involve the formation of molecular complexes between the drug and intracellular binding proteins, termed FKBPs. However, the biochemical target(s) for the effector RAP-FKBP complexes remain uncharacterized. As an approach to explore the mechanism of action of RAP, we have isolated three independent sets of somatic mutants of the YAC-1 murine T cell line with markedly reduced sensitivity to the drug's inhibitory effects on proliferation and on IL-1-induced IFN-gamma production. These mutants were still fully sensitive to FK-506, an immunosuppressant structurally related to RAP whose mode of action also involves an interaction with FKBPs. Furthermore, the 12-kDa FKBP, FKBP12, was detectable in immunoblots from cytosolic extracts and eluates from RAP-affinity matrix in the mutants as in wild-type cells, suggesting that the resistance to RAP in the mutants is not due to a lack of FKBP12 expression. Cell fusion experiments were conducted to further define the nature of the alterations imparting RAP resistance in these mutants. Clones deficient in either thymidine kinase or hypoxanthine-guanine phosphoribosyltransferase, suitable as fusion partners for aminopterin-based selection of hybrids were generated from the wild-type or mutant lines. In most instances, the hybrids derived from the fusion between RAP-sensitive clones and RAP-resistant clones exhibited a RAP-resistant phenotype. Similar results were obtained with hybrids between RAP-resistant YAC-1 clones and the RAP-sensitive EL-4 cell line. Therefore, the mutations that confer resistance to RAP in the present system are dominant. Altogether, our observations are consistent with a model where pharmacologically relevant targets for the RAP-FKBP complex, rather than FKBP, might be altered in the mutants such that the inactivation of these targets by the effector complex is prevented.
Subject(s)
Drug Resistance/genetics , Immunosuppressive Agents/pharmacology , Lymphoma, T-Cell/pathology , Mutation/genetics , Polyenes/pharmacology , Animals , Carrier Proteins/analysis , Carrier Proteins/genetics , Cell Division/drug effects , Cell Fusion/physiology , DNA-Binding Proteins/analysis , DNA-Binding Proteins/genetics , Flow Cytometry , Heat-Shock Proteins/analysis , Heat-Shock Proteins/genetics , Mice , Protein Serine-Threonine Kinases/analysis , RNA, Messenger/biosynthesis , Ribosomal Protein S6 Kinases , Sirolimus , Tacrolimus/pharmacology , Tacrolimus Binding Proteins , Tumor Cells, CulturedABSTRACT
Rapamycin (RAP) inhibits several biologic responses in the YAC-1 T cell lymphoma, including the serum-driven proliferation and cyclin A mRNA expression, the induction of Ly-6E Ag expression by IFN, and the induction of IFN-gamma production by IL-1. RAP also suppresses the enzymatic activity of the 70 kDa S6 protein kinase (pp70s6k). To define the mechanistic relationship between these multiple effects of RAP, we have generated stable somatic mutants with altered sensitivities to this drug. A first series of mutants, represented by the R19, 4R16, and 10R13 clones, showed markedly reduced sensitivity to the inhibitory effect of RAP on all biologic responses tested and on pp70s6k activity. Two other mutant types, R103 and R125, were both highly sensitive to RAP-mediated suppression of proliferation, of IL-1-induced IFN-gamma production, and of pp70s6k activity but differed in their Ly-6E response. This response was not affected by RAP in the R125 clone and was enhanced in the R103 clone. Therefore, the inhibitory effects of RAP on proliferation and IL-1-mediated IFN-gamma induction both appear associated with the inhibition of pp70s6k activity, whereas the modulation of Ly-6E induction is independent from the latter. Moreover, the cellular binding of [3H]dihydro-FK-506 was found to be blocked by RAP in all mutant types to the same extent as in wild-type YAC-1 cells, suggesting that the altered sensitivity to the effects of RAP in these mutants is not due to an inability of the drug to enter the cells or to interact with FKBP. Further biochemical characterization of the mutant cells described here is expected to help clarify the mechanisms of RAP action.